ATPγS Enhances the Production of Inflammatory Mediators by a Human Dermal Endothelial Cell Line via Purinergic Receptor Signaling  by Seiffert, Kristina et al.
ATPcS Enhances the Production of Inflammatory
Mediators by a Human Dermal Endothelial Cell
Line via Purinergic Receptor Signaling
Kristina Seiffert1, W. Ding1, John A. Wagner2 and Richard D. Granstein1
Adenosine 50-triphosphate (ATP) affects multiple intra- and extracellular processes, including vascular tone and
immune responses. Microvascular endothelial cells (EC) play a central role in inflammation by recruitment of
inflammatory cells from blood to tissues. We hypothesized that ATP (secreted by neurons and/or released after
perturbation of cutaneous cells) may influence secretion of inflammatory messengers by dermal microvascular
EC through actions on purinergic P2 receptors. Addition of the hydrolysis-resistant ATP analogue, adenosine
50-O-(3-thiotriphosphate) (ATPgS), to subconfluent cultures of the human microvascular endothelial cell-1
(HMEC-1) cell line led to a dose- and time-dependent increase in release of IL-6, IL-8, monocyte chemoattractant
protein-1, and growth-regulated oncogene a. Both ATPgS-induced release and basal production of these
proteins were significantly inhibited by the purinergic antagonists pyridoxal-50-phosphate-6-azophenyl-20,
50-disulfonic acid (PPADS), pyridoxal-50-phosphate-6(20-naphthylazo-6-nitro-40,80-disulfonate), and suramin.
ATPgS increased expression of intercellular adhesion molecule-1 (ICAM-1), whereas suramin and PPADS
decreased both ATPgS-induced and basal ICAM-1 expression. Using PCR, we found that HMEC-1 strongly
express mRNA for the P2X4, P2X5, P2X7, P2Y2, and P2Y11 receptors and weakly express mRNA for P2X1 and P2X3
receptors. Purinergic nucleotides may mediate acute inflammation in the skin and thus contribute to
physiological and pathophysiological inflammation. For example, ATP may contribute to both the vasodilation
and the inflammation associated with rosacea.
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INTRODUCTION
Adenosine 50-triphosphate (ATP) is an ubiquitous carrier of
chemical energy and a building block of genetic material in
all living organisms (Brake and Julius, 1996). ATP also serves
as an extracellular signaling molecule involved in vascular
tone, synaptic transmission, and cell death (Bodin and
Burnstock, 2001; Burnstock, 2002). Additionally, ATP modu-
lates immune responses (Di Virgilio et al., 2005).
ATP can be released into the extracellular environment via
non-lytic mechanisms and also, more frequently, as a
consequence of cell damage or acute cell death (Di Virgilio
et al., 2001). It activates purinergic P2 receptors which, based
on their molecular structures and signal transduction
pathways, belong to either the ionotropic P2X receptor
family or the metabotropic P2Y receptor family (Lambrecht,
2000). There are currently seven recognized mammalian P2X
receptors (P2X17) and at least eight P2Y receptors (P2Y1,
P2Y2, P2Y4, P2Y6, P2Y11, P2Y12, P2Y13, P2Y14) (Di Virgilio
et al., 2001; Abbracchio et al., 2003).
Purinergic receptors are expressed on a multitude of cells
that influence immune functions, including macro- and
microvascular endothelial cells (EC) (Yamamoto et al.,
2000; Wang et al., 2002; Burnstock and Knight, 2004) and
there is evidence that ATP increases leukocyte locomotion
(Saito et al., 1991) and adhesion of leucocytes to EC via
purinergic receptors (Dawicki et al., 1995; Parker et al.,
1996; Rounds et al., 1999).
Microvascular EC play a central role in inflammation
through recruitment of immunocompetent cells from the
blood to tissues. They regulate traffic of leukocytes to
inflamed sites, such as the skin, by release of proinflamma-
tory cytokines and chemokines and expression of adhesion
See related commentary on page 943
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molecules (Swerlick and Lawley, 1993). We hypothesized
that ATP-signaling may play a role in the recruitment and
directed migration of leukocytes to the skin by affecting the
production of cytokines, chemokines, and adhesion mole-
cules in human dermal microvascular EC.
To avoid rapid hydrolysis of ATP by endothelial cell
endonucleotidases, we used the hydrolysis-resistant ATP
analogue adenosine 50-O-(3-thiotriphosphate) (ATPgS). We
also studied the effects of other purinergic agonists and
antagonists. Herein we report that transformed microvascular
EC (human microvascular endothelial cell-1 (HMEC-1))
express mRNA for a distinct repertoire of purinergic
receptors. Furthermore, receptor engagement by ATPgS leads
to increased production and expression of proinflammatory
cytokines and chemokines as well as intercellular adhesion
molecule-1 (ICAM-1) by these cells. We hypothesize that
nucleotides, released by local nerve cells, EC, and/or
keratinocytes, augment inflammatory responses in the skin.
RESULTS
ATPcS induces production of IL-6, IL-8, monocyte chemotactic
protein-1, and growth-regulated oncogene a in HMEC-1 cells
During the pathogenesis of inflammatory skin diseases,
dermal microvascular EC recruit inflammatory cells via the
expression of adhesion molecules and the release of
cytokines, among them IL-6 and IL-8 (Swerlick and Lawley,
1993). To determine whether nucleotides enhance the
secretion of these cytokines, we used the transformed dermal
microvascular EC line HMEC-1. These cells retain the
properties of microvascular EC and are frequently used to
study EC function (Xu et al., 1994; Goebeler et al., 1997).
Subconfluent HMEC-1 were incubated for 4, 8, 12, or
24 hours in depleted medium (ie endothelial cell basal
medium with 2% fetal calf serum, without epithelial growth
factor or hydrocortisone, see Materials and Methods) in the
presence or absence of 100mM ATPgS. Supernatants were
collected after the indicated times, and IL-6- or IL-8
production was measured by enzyme-linked immunosorbent
assay (ELISA). Both cytokines were spontaneously produced
by HMEC-1 and accumulated over time (Figure 1). Addition
of ATPgS significantly increased both IL-6- and IL-8 produc-
tion when assessed after 12 and 24 hours for IL-6 (Figure 1a)
and after 8, 12, and 24 hours for IL-8 (Figure 1b).
To attract leukocytes to areas of inflammation, EC also
express adhesion molecules and produce a number of
chemokines that bind to and signal through specific receptors
on leukocytes (Johnston and Butcher, 2002). Apart from IL-8
(also known as CCL8), these include the chemokines
monocyte chemotactic protein-1 (MCP-1) (CCL2), regulated
upon activation, normal T cell expressed and secreted protein
(RANTES) (CCL5), secondary lymphoid-tissue chemokine
(SLC) (CCL21), and growth-regulated oncogene a (GROa)
(CXCL1) (Cid, 2002). In preliminary screening experiments
using proteome arrays for multiplexed detection and quanti-
fication of cytokines and chemokines (Searchlight; Pierce
Biotechnology, Woburn, MA), HMEC-1 produced only low
levels of IL-1a, IL-1b, eotaxin, and thymus and activation
regulated chemokine (TARC), and ATPgS stimulation did not
change expression under the conditions we used (data not
shown). Production of E-selectin and RANTES was easily
detected in this assay, and also not changed by addition of
ATPgS (data not shown). GROa and MCP-1 secretion, on the
other hand, were clearly increased by ATPgS at either 10 or
100mM (Figure 2). Thus, we chose to study the effects of
purinergic receptor antagonists on the expression of IL-6, IL-8,
MCP-1, and GROa.
Purinergic antagonists suramin, pyridoxal-50-phosphate-6-azo-
phenyl-20,50-disulfonic acid, and pyridoxal-50-phosphate-6(20-
naphthylazo-6-nitro-40,80-disulphonate inhibit production of
IL-6, IL-8, MCP-1, and GROa in HMEC-1 cells
To test whether the increase in IL-6, IL-8, GROa, and MCP-1
production by ATPgS is mediated by cell surface purinergic
receptors, we preincubated subconfluent HMEC-1 with the
purinergic antagonists suramin, pyridoxal-50-phosphate-
6-azophenyl-20,50-disulfonic acid (PPADS) and pyridoxal-
50-phosphate-6(20-naphthylazo-6-nitro-40,80-disulphonate)
(PPNDS) at either 100 mM (Figure 2a) or 1 mM (Figure 2b) and
then exposed the cells to 10 or 100 mM ATPgS, respectively, or
incubated them in the absence of agonist.
We observed that the HMEC-1 cell line varies in the
amount of overall cytokine and chemokine production
between experiments, depending on the number of cell
culture passages, the level of confluency and different
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Figure 1. (a) IL-6 and (b) IL-8 accumulate in HMEC-1 supernatants over time
and are increased by ATPgS. HMEC-1 cells were incubated with and without
ATPgS 100mM for 4, 8, 12, or 24 hours and their IL-6 and IL-8 secretion into
the supernatant was measured by ELISA (mean7standard deviation;
*Po0.05; **Po0.01 for ATPgS vs baseline); values represent one experiment
performed in triplicate.
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batches of serum used for maintenance. However, regardless
of the overall amount of cytokine, ATPgS always increased
production, whereas the antagonists always decreased basal
and induced cytokine release.
The IL-8, GROa, and MCP-1 production induced by 10 mM
ATPgS was significantly inhibited by suramin and PPNDS at
100mM in most instances, but not by PPADS (Figure 2a). In
experiments examining the ability of inhibitors at a concen-
tration of 1 mM to inhibit the action of 100mM ATPgS, all
antagonists significantly inhibited ATPgS-induced IL-6, IL-8,
GROa, and MCP-1 production (Figure 2b). PPADS, though,
was still the least effective antagonist. All antagonists, apart
from PPADS for GROa, also decreased the basal expression
of all four chemokines and cytokines, suggesting that the
relevant receptors may be partially activated in cell culture
even in the absence of exogenous agonist.
The expression of ICAM-1 in HMEC-1 cells is increased
by ATPcS and inhibited by the purinergic antagonists suramin
and PPADS
To recruit leukocytes from the blood to inflamed tissues, EC
express adhesion molecules, such as ICAM-1 and vascular
cellular adhesion molecule-1 (VCAM-1), that facilitate
migration of lymphocytes into inflamed tissues (Pober et al.,
2001). To determine whether ATPgS also induces adhesion
molecule expression in EC or whether adhesion molecule
expression can be blocked by purinergic antagonists, HMEC-1
cells were incubated in depleted medium with suramin,
PPADS, or PPNDS (1 mM) for 1 hour before exposing them to
ATPgS 100mM. We measured cell surface expression of
ICAM-1 and VCAM-1 by FACS analysis at 24 hours of culture.
HMEC-1 constitutively express ICAM-1 (Figure 3), whereas
VCAM-1 is not expressed (data not shown). ATPgS significantly
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Figure 2. ATPcS induces IL-6, IL-8, GROa, and MCP-1 secretion in HMEC-1 cells, and purinergic antagonists inhibit both basal and ATPcS-induced production
of these cyto/chemokines. HMEC-1 cells were maintained in depleted medium throughout the experiment. After reaching subconfluence, HMEC-1 cells were
incubated with (a) 100 mM or (b) 1 mM purinergic antagonists for 30 minutes before treatment with 10 or 100 mM ATPgS, respectively. Some wells received (a) 10
or (b) 100 mM ATPgS without antagonists. Some wells were cultured without addition of ATPgS or inhibitors. Conditioned supernatants were collected after
24 hours and cytokine/chemokine secretion measured by ELISA (mean7standard deviation; **Po0.01; *Po0.05). Data shown in (a) are one experiment
representative of four independent experiments, each of which was run in triplicate. Data shown in (b) are one experiment representative of three independent
experiments. The experiment shown was run in quintuplicate. Statistics are based on comparisons of the mean values of the individual experiments.
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increased ICAM-1 expression (Figure 3), but it did not induce
VCAM-1 expression (not shown). The purinergic antagonists,
suramin, PPADS, and PPNDS, all inhibited the ATPgS-
induced ICAM-1 expression (suramin4PPADS4
PPNDS). The basal expression of ICAM-1 was inhibited by
suramin, but not by PPADS or PPNDS. Indeed, PPNDS
appeared to modestly increase ICAM-1 expression.
Purinergic agents and cell death
As extracellular ATP has been reported to cause apoptosis
and cell death in various cell types, including lymphocytes
(Dubyak and el-Moatassim, 1993) and keratinocytes (Greig
et al., 2003a), we measured the effect of ATPgS and the
purinergic antagonists on the viability of the HMEC-1 cell
line. HMEC-1 were treated with 100 mM ATPgS alone, ATPgS
100mM together with either one of the antagonists suramin,
PPADS, or PPNDS (1 mM), or suramin, PPADS, or PPNDS
alone. After 24 hours, cells were harvested, and annexin V
staining as well as propidium iodine uptake was measured by
FACS. Annexin V binds to the membrane phospholipid
phosphatidylserine, which is translocated to the outer plasma
membrane leaflet in cells undergoing apoptosis. Propidium
iodine incorporation serves as a direct measure of cell death,
since living cells exclude the dye propidium iodine. The
annexin-stain in unstimulated cells varied from 1 to 5% in
different experiments. Nevertheless, when compared to
unstimulated cells, 100mM ATPgS moderately increased the
number of annexin-positive cells (2–12%), but did not
increase 24 hours cell death (data not shown). The antago-
nists suramin, PPADS, and PPNDS seemed to protect HMEC-1
from the ATPgS-induced annexin-positivity. PPADS and
PPNDS may even have a small protective effect when
compared to apoptosis in unstimulated HMEC-1. Never-
theless, the number of dead cells remained relatively small (in
the range of 1.3–3.2%) in all of the conditions studied. Thus,
ATPgS does not appear to substantially induce cell death
in this line.
The number of annexin-positive cells could indicate that
there is a modest increase of apoptosis induced by ATPgS.
This is less likely, though, because we did not observe other
signs of apoptosis, such as cell shrinkage (as indicated by a
decrease in forward scatter in the FACS analysis), and no
increased cell death after 24 hours. Another possibility is a
process of rapid exposure of phosphatidylserine followed by
shedding of microvesicles containing cytokines, as reported
by MacKenzie et al. (2001) and Wilson et al. (2004) in
monocytes and macrophages, respectively, through activa-
tion of the P2X7 receptor. This so-called ‘‘phosphatidylserine
flip’’ is reversible and not associated with cell death and
it is conceivable that a similar mechanism was occurring in
our study.
HMEC-1 cells express P2X and P2Y receptors
To determine which purinergic receptors are expressed by
HMEC-1 cells and may be responsible for the ATPgS-induced
changes in cytokine/chemokine expression, we used the PCR.
Since keratinocytes express purinergic receptors (Dixon et al.,
1999; Greig et al., 2003a) and could yield a confounding
signal when a highly sensitive method such as PCR is
employed with freshly isolated dermal EC, we used the cell
line HMEC-1 as a surrogate for native cells. We found strong
expression of the P2X4, P2X5, P2X7, P2Y2, and P2Y11
receptors (Figure 4). Expression of P2X1 was faint, whereas
P2X3 was faint and only variably detectable. We did not
detect the expression of P2X2, P2X6, P2Y1, P2Y4, P2Y6,
P2Y12, and P2Y13. In every case, the PCR product was the
size predicted from the gene sequence (see Table 1). We did
not test for mRNA expression of the P2Y14 receptor, which
displays structural similarities to known members of the P2Y
receptor family, but is activated by UDP-glucose and related
sugar nucleotides instead of adenine or uracil nucleotides
(Abbracchio et al., 2003). Thus, P2X4, P2X5, P2X7, P2Y11,
and P2Y12 are potential targets for ATPgS.
Purinergic agonists increase IL-6 production by HMEC-1 with
different potencies
To further address the question of which P2-receptor may be
responsible for the cytokine and chemokine-inducing effect
of ATPgS, we determined the effect of a panel of agonists with
different known potencies at different P2 receptors. Subcon-
fluent HMEC-1 cells were incubated with the agonists,
2-methylthioATP (2-MeSATP), a,b-methylene ATP (a,b-
meATP), ATP, ATPgS, benzoylbenzoylATP (BzATP), and
uracil triphosphate (UTP) for 24 hours. The supernatants were
then collected and IL-6 measured by ELISA. The agonists
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Figure 3. ATPcS induces ICAM-1 expression in HMEC-1, and the antagonists
suramin and PPADS inhibit both basal and ATPcS-induced ICAM-1
expression. HMEC-1 cells were maintained in depleted medium, and were
incubated with purinergic antagonists (1 mM) 1 hour before treatment with
ATPgS 100 mM. After 24 hours the cells were collected, stained with anti-
ICAM-1 antibodies, and ICAM-1 expression was measured by FACS analysis.
(a) Histograms depicting the ICAM-1 staining profiles for the conditions
indicated; (b) arithmetic mean of ICAM-1 fluorescence intensity
(MnX)7standard deviation recorded for all conditions (**Po0.01);
experiment representative of two independent experiments, each of which
was run in triplicate.
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induced IL-6 secretion with the following potencies: ATP4
ATPgSbUTP4BzATPb2-MeSATP¼ a,b-meATP (Figure 5).
Although ATP and ATPgS induced IL-6 at low concentrations
(1–3 mM) and continued to strongly increase IL-6 at higher
concentrations (100 mM), UTP-induced IL-6 secretion
reached an early plateau at around 10–30 mM. BzATP-treated
HMEC-1 produced only low amounts of IL-6 starting at 30 mM,
whereas 2-MeSATP and a,b-meATP-treated HMEC-1 cells
produced almost no IL-6. As discussed in more detail below,
these data are most consistent with a regulatory role for P2Y2
or P2Y11, but a role for the other receptors cannot be
excluded.
DISCUSSION
Research regarding the effect of nucleotides on EC physiology
has long been dominated by its importance in regulation of
vascular tone and platelet aggregation. More recently, ATP
has been appreciated as a regulator of directed migration of
leukocytes towards and adherence to activated EC (Dawicki
et al., 1995; Parker et al., 1996; Rounds et al., 1999). Our
data provide evidence for a novel mechanism, by which ATP
may influence microvascular EC to attract leukocytes to areas
of localized inflammation, such as the skin. EC are important
sources of a number of proinflammatory cytokines and
chemokines, among them IL-6, IL-8 (CCL-8), GROa (CXCL1),
and MCP-1 (CCL2) (Swerlick and Lawley, 1993) and express
adhesion molecules such as ICAM-1 and VCAM-1 (Lidington
et al., 1999). Induction of these factors has been achieved by
stimulation with IL-1b, IFN-g, and tumor necrosis factor (TNF)
a in both freshly prepared human dermal microvascular
endothelial cells and transformed HMEC-1 cells (Goebeler
et al., 1997; Lidington et al., 1999). Similarly, by upregulating
the secretion and expression of IL-6, IL-8, GROa, MCP-1, and
ICAM-1, ATP may catalyze immune responses by supporting
leukocyte activation and creating a soluble gradient to
guide leukocyte migration. In fact, IL-6 functions as a broad
stimulator of immune responses (Paquet and Pierard,
1996). IL-8 and GROa, both members of the CXC subfamily
of chemokines, bind to the endothelium and preferentially
attract and activate neutrophils (Rot et al., 1996; Johnston
and Butcher, 2002). MCP-1 (CCL2), a member of the CC
subfamily, has been shown to stimulate degranulation and
respiratory burst in monocytes (Rollins et al., 1991), to
chemoattract and stimulate histamine release from basophils
(Kuna et al., 1992), and to chemoattract both CD4þ and
CD8þ T lymphocytes (Loetscher et al., 1994) as well as
memory T cells (Carr et al., 1994). Interestingly, MCP-1 is
secreted at both the luminal and abluminal sides of EC.
Because apically released MCP-1, due to flow conditions, is
more readily diluted than the MCP-1 fraction secreted
into the subendothelial matrix, a soluble gradient that
promotes transendothelial migration of monocytes is
established (Randolph and Furie, 1995). In addition, ICAM-1
also leads to firm leukocyte adhesion and subsequent
transmigration (Pober et al., 2001). Thus, our data suggest
that ATP may play an important role in inflammatory
skin conditions by stimulating nonspecific immune responses
as well as by specifically directing neutrophils, monocytes,
and T-lymphocytes from the blood to areas of tissue
perturbation.
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Figure 4. HMEC-1 cells express mRNA for the purinergic receptors P2X1, P2X3, P2X4, P2X5, P2X7, P2Y2, and P2Y11. Poly(A)
þRNA was extracted from
unstimulated HMEC-1 and DNase-treated to remove genomic DNA contamination (designated as þ ). RNA extracted from HMEC-1 without DNase digestion,
and confirmed to contain genomic DNA, served to demonstrate that the primer pairs could detect the relevant sequence (designated as þ þ ). RT-PCR was
performed using primers designed from sequences in GenBank (see Table 1). To demonstrate that PCR products were derived from RNA rather than
contaminating DNA, reverse transciptase was omitted from the reaction mixture containing DNase digested HMEC-1 mRNA (designated as ). Receptor
expression was confirmed with at least three different experiments, each of which had a separate RNA isolation.
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Table 1. RT-PCR primers and reaction conditions for P2-receptors
Primer sequences GenBank No.
Reaction conditions
(1C/30 second) Expected size (bp)
P2X1 NM_002558 94
Sense: tgt ggc ctt caa cga cac tg 54 117
Anti: gga ccc tgt tct tag ctc tct gg 72
P2X2 NM_170682 (variant 1) 94 194(1)
Sense: aag ttc agc ctg att ccc acc or 55 or
Anti: aat aca cgg gca agg gtc ac NM_170683 (variant 4) 72 272(4)
P2X3 AB016608 94
Sense: cct cct tcc caa cct gac ag 50 102
Anti: aac ttg acc acg tcc cct acc 72
P2X4 BC033826 94
Sense: ggc gga tta tgt gat acc ag 58 460
Anti: tgt gtt ctc cac tat ttt gc 72
P2X5 NM_002561 94
Sense: cgt gaa ttg cct ctg ctt ac 53 163
Anti: act ttg ctc tgt gat ggc tg 72
P2X6 AF065385 94
Sense: gaa agc aac cgc caa ctc tg 58 175
Anti: gga atg ggt tgg caa gtg g 72
P2X7 BC011913 94
Sense: aga tcg tgg aga atg gag tga ag 53 399
Anti: ttc tcg tgg tgt agt tgt ggc cg 72
P2Y1 BC074785 94
Sense: tgt ggt gta ccc cct caa gtc cc 53 260
Anti: atc cgt aac agc cca gaa tca gc 72
P2Y2 BC012104 94
Sense: cca ggc ccc cgt gct cta ctt tg 53 367
Anti: cat gtt gat ggc gtt gag ggt gt 72
P2Y4 NM_002565 94
Sense: cgt ctt ctc gcc tcc gct ctc tc 53 433
Anti: gcc ctg cac tca tcc cct ttt ct 72
P2Y6 NM_176798 (variant 2) 94
Sense: cac atc acc aag aca gcc ta 53 488
Anti: cct taa tgt ggt ttc ccc ag 72
P2Y11 BC073827 94
Sense: gtg gtt gag ttc ctg gtg gcc gt 58 238
Table 1 continued on the following page
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Because ATP is rapidly hydrolyzed to ADP, adenosine
monophosphate, and finally adenosine through the action of
ectonucleotidases, which are expressed on EC (Dubyak and
el-Moatassim, 1993; Brake and Julius, 1996), we used the
hydrolysis-resistant, long-lived ATP agonist ATPgS for func-
tional studies. In contrast to the proinflammatory function
associated with ATP, adenosine dose-dependently inhibits
the release of IL-6 and IL-8, as well as the expression of
E-selectin and VCAM-1 by activated EC (Bouma et al.,
1996). The breakdown of ATP to adenosine happens rapidly
under physiological conditions, but the relative concentra-
tion of ATP and adenosine depends on a number of
factors. For example, the local concentration of ATP during
inflammation may increase as a consequence of inactivation
of ecto-ATPases by oxygen radicals (Robson et al., 1997).
To achieve a significant cyto- and chemokine stimulation
above background levels, we had to use concentrations of
ATPgS of 10–100mM. This relatively high concentration seems
to be physiological, though, as mammalian cells contain
huge amounts (5–10 mM) of ATP in their cytosol (Di Virgilio
et al., 2001). Interestingly, maximal blood levels of ATP of
10–20 mM were measured after human skin incision (Born and
Kratzer, 1984). Because endothelial ectonucleotidases are
effective scavengers of ATP, actual concentrations in the
immediate vicinity of release may be even higher (Gordon
1986). Thus, an ATP gradient capable of inducing cytokine
and chemokine release, resulting in leukocyte chemotaxis
and activation, is likely to occur at sites of cell or tissue
damage and possibly also after non-lytic release. ATP can,
indeed, be released from EC under physiological conditions
(Liu et al., 2004). Of note, MCP-1 generally showed a lesser
induction by ATPgS than IL-6, IL-8, and GROa. Perhaps
MCP-1 expression is already promoted by ATP present in
the medium, so that it cannot respond strongly to addition
of exogenous ATP. Also, as we could not only inhibit
ATP-induced, but also spontaneous cytokine/chemokine
secretion well beyond basal levels, our data suggest that
ATP is able to function as an autocrine and/or paracrine
signal for cytokine and chemokine secretion in EC. Possible
other sources of paracrine ATP release are neuronal
cells following inflammation and injury (Sawynok and Liu,
2003), and human keratinocytes under static conditions
(Dixon et al., 1999) and after chemical injury (Mizumoto
et al., 2003).
In part because of the ever expanding number of clon-
ed purinergic receptors and the paucity of useful li-
gands, especially subtype-selective agonists and antagonists
(Lambrecht, 2000), P2 receptor expression has not been
characterized fully in vasculature. In human macrovascular
EC from multiple sources, expression of P2X17 as well as
P2Y1, P2Y2, P2Y4, P2Y6, and P2Y11 has been documented
(Pirotton et al., 1996; Yamamoto et al., 2000; Glass et al.,
2002; Ray et al., 2002; Schwiebert et al., 2002; Wang et al.,
2002), with P2X4 being predominantly expressed (Yamamoto
et al., 2000). To our knowledge, there is only one report on
the expression of purinergic receptors in skin microvessel
cells to date. Yamamoto et al. (2000) showed mRNA
expression of P2X1 and P2X4 by PCR, but only P2X4
expression was confirmed by Northern analysis. We confirm
a strong expression of P2X4 and a weak expression of P2X1
mRNA in the human dermal microvascular EC line HMEC-1.
Additionally, we found robust expression of mRNA for the P2
receptors P2X5, P2X7, P2Y2, and P2Y11, but only variable
expression for P2X3 with our technique. If this receptor is
expressed, it appears to be at a low level.
Table 1. continued
Primer sequences GenBank No.
Reaction conditions
(1C/30 second) Expected size (bp)
Anti: cca gca ggt tgc agg tga aga gg 72
P2Y12 BC017898 94
Sense: tgt cca ggg tca gat tac aa 52 301
Anti: aca gtg tag agc agt ggg aa 72
P2Y13 NM_023914 94
Sense: ctt cta ctg ttt ggg tgt gt 53 237
Anti: gga tgt tac tga ttg tgg gt 72
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Figure 5. Purinergic agonists differentially affect IL-6 production in HMEC-1
cells. HMEC-1 cells were incubated with ATP, ATPgS, UTP, BzATP, UTP,
a,b-meATP, and 2-MeSATP for 24 hours at the concentrations indicated.
Conditioned supernatants were collected and IL-6 secretion measured by
ELISA. Combined data from three independent experiments, each of which
was performed in triplicate, are presented (mean7standard deviation).
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Owing to the lack of specific agonists and antagonists for
individual purinergic receptors, it has been difficult to define
which receptors are ultimately involved in distinct ATP
effects. We were able to block cytokine and chemokine
production with several non-specific purinergic blockers,
PPADS being the least effective among them. PPADS,
PPNDS, and suramin are all non-selective (but non-universal)
P2 antagonists, and block multiple purinergic receptors with
different efficiencies (Ralevic and Burnstock, 1998). In regard
to PPADS, it is interesting that, if used at 1–10 mM, an effective
blockade of PPADS-sensitive P2 receptors should be
achieved, with little or no inhibition of ecto-nucleotidases
(Lambrecht, 2000). Nevertheless, it is weak or ineffective as
an antagonist (IC410 mM) at P2X4, P2X7, P2Y2, and P2Y11
receptors (Lambrecht, 2000). Based on the efficacy profiles
of agonists (ATP4ATPgSbUTP4BzATPb2MeSATP¼ a,b-
meATP) and antagonists seen in this study, P2X7 seems an
unlikely candidate for the induction of cytokines, since
ATPgS has been shown to not activate or only weakly activate
this receptor, whereas BzATP should be its most potent
agonist (Lambrecht, 2000; Jacobson et al., 2004). Although
PPNDS has been described as a more potent antagonist than
PPADS at P2X1-like receptors (Lambrecht, 2000), P2X1 and
also P2X2 seem unlikely targets, as BzATP and 2-MeSATP are
reportedly stronger agonists than ATP (Jacobson et al., 2002).
P2X4 receptors are unlikely targets as well, as they are
relatively insensitive to suramin (Jacobson et al., 2002),
which proved to be the strongest antagonist in our studies.
P2X5 receptors are sensitive to suramin (IC value 2.9 mM), but
they are even more responsive to PPADS (IC value 0.2 mM) (Bo
et al., 2003), which was the weakest antagonist in our study.
This leaves us with P2Y2 and P2Y11. At P2Y2 ATP and UTP
are equipotent at low concentrations from 3 to 10 mM,
whereas 2-MeSATP and a,b-meATP have no or weak activity
(Jacobson et al., 2002). Nevertheless, that suramin is only a
weak antagonist at P2Y2 (Ralevic and Burnstock, 1998)
would argue against P2Y2 as the only receptor involved. The
other candidate is P2Y11. Suramin is the most effective
antagonist at P2Y11, whereas PPADS is inactive (Communi
et al., 1999; Wilkin et al., 2001). Although this antagonist
profile would fit the data shown in the present paper, ATPgS
and even BzATP should be more potent than ATP at the
P2Y11 receptor (Communi et al., 1999; Wilkin et al., 2001),
which was not the case in our experiments. In summary, the
agonist and antagonist profile we see regarding IL-6 produc-
tion does not fit signaling through one receptor alone, but
may reflect combined signaling through several receptors,
most likely of the P2Y subtype, that is P2Y2 and P2Y11.
Of course, the lack of absolute specificity of these
antagonists makes this hypothesis speculative. One has to
keep in mind as well that ATPgS has a slightly different
receptor activation profile that ATP (for an extensive list of
agonist potencies see Jacobson et al., 2002; Burnstock and
Knight, 2004) and in vivo ATP may activate additional
receptors, such as P2X7. Nevertheless, our data show that the
effect of ATP on EC cytokine and chemokine secretion is a
specific, receptor-mediated process. Of note, though, PPNDS
was the least effective antagonist in blocking ATPgS-induced
ICAM-1 expression and it was ineffective in blocking basal
ICAM-1. Thus, purinergic signaling might be different for
adhesion molecules as opposed to cytokines and chemo-
kines.
Taken together, we provide evidence for a novel
mechanism by which ATP may influence localized inflam-
matory reactions. ATP may amplify the immune response by
generating additional inflammatory mediators and, thus,
function as an alarm signal to alert leukocytes to tissue
damage or infection through activation of EC-derived signals.
This mechanism might be operational in many inflammatory
skin conditions. It is conceivable, for example, that in
rosacea, which is characterized histologically by dilated
hyperaemic capillaries and a mononuclear inflammatory
infiltrate (Georgala et al., 2001), ATP not only helps to attract
leukocytes but also enhances intraluminal blood flow (by
inducing NO production) (Liu et al., 2004). Furthermore, it is
likely that ATP released by microvascular EC could also act
on purinergic receptor-expressing skin cells, such as keratino-
cytes and fibroblasts, where ATP has been shown to increase
intracellular Ca2þ , cell growth and differentiation, release of
IL-6, and apoptosis (Solini et al., 1999; Burrell et al., 2003;
Greig et al., 2003b; Koizumi et al., 2004; Inoue et al., 2005).
Thus, ATP may be a unifying transmitter in a complex
network of inflammatory reactions within the skin. The trigger
factors leading to ATP release and the determination of which
purinergic receptors are responsible for each EC response
need to be addressed in future studies.
MATERIALS AND METHODS
Media and cell lines
The transformed human dermal microvascular EC line HMEC-1
(Ades et al., 1992), which was immortalized by simian virus 40
transformation, was the kind gift of T.J. Lawley (Emory University,
Atlanta, GA). These cells retain several properties of dermal
microvascular EC including cell adhesion molecule expression and
cytokine production (Swerlick and Lawley, 1993). HMEC-1 cells
were cultured in endothelial cell basal medium (Cambrex, Walk-
ersville, MD) containing 10% fetal bovine serum (Life Technologies,
Gaithersburg, MD), epidermal growth factor (10 ng/ml, BD Bio-
sciences, Bedford, MA), hydrocortisone (1 mg/ml; Sigma-Aldrich, St
Louis, MO), and 100 U/ml penicillin/100 mg/ml streptomycin (Life
Technologies), in a humidified atmosphere at 371C with 5% CO2. In
some experiments, the cells were kept in endothelial cell basal
medium supplemented only with 2% fetal calf serum and penicillin/
streptomycin without epithelial growth factor or hydrocortisone
(referred to as depleted medium) in order to avoid any possible
immunomodulating effects of these agents during agonist/antagonist
treatment.
Nucleotides and antagonists
ATP, ATPgS, PPADS, PPNDS, and suramin were purchased from
Sigma-Aldrich (St Louis, MO).
RNA isolation and RT-PCR
Total RNA was extracted from HMEC-1 cells using a total RNA
extraction kit as per manufacturer’s instructions (RNeasy total RNA
Mini kit; Qiagen, Santa Clarita, CA). As small amounts of DNA may
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contaminate the sample with this method of extraction, an additional
DNA degradation step was included (RNase free DNase set;
Qiagen). Oligonucleotide primers were designed from published
sequences for the mRNA of human P2X (P2X17) and P2Y (P2Y1,
P2Y2, P2Y4, P2Y6, P2Y11, P2Y12, P2Y13) receptor subtypes using the
Primer ExpressTM (PE Applied Biosystems, Foster City, CA) and Oligo
4.0 (Molecular Biology Insights, Inc., Cascade, CO) software. The
primers used in this experiment, their reaction conditions, and the
expected size of the amplified products are listed in Table 1. The
sequences amplified by the primer pairs P2X4, P2X7, and P2Y12 span
several introns. The total RNA (0.5 mg per 20 ml reaction) was
reverse-transcribed into complementary DNA with random hexa-
nucleotide primers and SuperscriptTM II reverse transcriptase (Invitro-
gen, Carlsbad, CA) following the manufacturer’s instructions. To
verify that the amplified product did not come from genomic DNA
contamination, we omitted the reverse transcriptase from some
reactions. Two microliters of the complementary DNA were
transferred to a PCR mixture containing 375 nM of each specific
primer and Platinum PCR Supermix (Invitrogen) for a total reaction
volume of 40 ml and the PCR reaction was carried out with a thermal
cycler (Gene Amp PCR system 9,700; Perkin Elmer, Wellesley, MA)
for 40 cycles. The PCR product was gel-electrophoresed in 1%
agarose, stained with ethidium bromide, and visualized with UV
radiation. A RNA sample that was extracted without DNase
digestion and showed genomic DNA contamination, served as the
positive control for all primer pairs, except P2Y12. A sequence of the
expected size for P2Y12 was amplified from human platelet RNA.
Cytokine assays
To measure IL-6, IL-8, GROa, and MCP-1 secretion by EC, HMEC-1
were plated at a concentration of 0.5 106 cells/well in six-well
plates in triplicate in endothelial cell basal medium as described
above. After allowing cells to firmly adhere, the medium was
changed to depleted medium. After 24 hours, the cells were washed
and fresh medium containing the ATP-antagonists PPADS, PPNDS,
or suramin at concentrations from 100 mM to 1 mM was added for
1 hour to some wells as indicated in Figure 2. ATP or ATPgS was then
added as indicated at concentrations of 10–100 mM to the appropriate
wells and cells were left for various time periods (4, 8, 12, and
24 hours) before harvest of the conditioned supernatants. In some
experiments, other purinergic agonists (2-MeSATP, a,b-meATP, ATP,
ATPgS, BzATP, and UTP) were added to subconfluent cells in
depleted medium at concentrations from 1 to 100 mM, and the
conditioned supernatants were harvested 24 hours later.
IL-6 and IL-8 secretion was quantified by sandwich ELISA, with
antibodies and standards purchased from BD Pharmingen (San Diego,
CA). Purified rat anti-human IL-6 or purified mouse anti-human IL-8
served as the primary (capture) antibodies, and purified human IL-6/
IL-8 as the standard. Biotinylated mouse anti-human IL-8 mAb or
biotinylated rat anti-human IL-6 mAb, the secondary (detection)
antibodies, were detected by streptavidin–horseradish peroxidase in a
1:1,000 dilution. The amount of bound cytokine was visualized by
addition of a 1:1 mixture of color reagent A (H2O2) and color reagent
B (tetramethylbenzidine) (R&D systems, Minneapolis, MN). The color
reaction was stopped with 2 N H2SO4 and the level of colored reaction
product was measured spectrophotometrically at 450 nm.
GROa and MCP-1 production was quantified by sandwich ELISA
(DuoSets ELISA Development system; R&D systems) as well. These
kits include mouse anti-human GROa or MCP-1 as the primary
(capture) antibody, recombinant human GROa or MCP-1 as the
standard, and biotinylated goat anti-human GROa/MCP-1 as the
secondary (detection) antibody. Streptavidin–horseradish peroxidase
conjugate was added at a 1:1,000 dilution, followed by color
development as described above.
Flow cytometry
HMEC-1 cells were cultured and treated with purinergic agonists
and antagonists as described above. After removal of 24-hour-
conditioned supernatants, cells were detached by trypsinization,
and resuspended in phosphate-buffered saline containing 2% fetal
calf serum and 0.02% sodium azide. To detect apoptotic and/or
dead cells, annexin V (Caltag Laboratories, Burlingame, CA) and
propidium iodine (BD Pharmingen) were added as per manufac-
turer’s instructions for 20 minutes. In a separate set of experiments,
the cells were stained with phycoerythrin-conjugated mouse anti-
human ICAM-1 (CD54) and phycoerythrin-conjugated mouse anti-
human VCAM-1 (CD 106) antibodies (BD Pharmingen; 5 ml/5 105
cells). Phycoerythrin-conjugated mouse anti-human IgGk antibodies
served as isotype controls. Apoptosis (Annexin V-FITC apoptosis
detection kit, BD Pharmingen) and cell death was analyzed by FACS
on a Beckman-Coulter XL flow cytometer.
Statistical analysis
For the time course of IL-6 and IL-8 induction (Figure 1), statistical
differences among ATPgS-treated and non-treated groups were
determined using Excel software (Microsoft Office X; Microsoft,
Redmond, VA) and tested by the two-tailed Student’s t-test for
independent samples. For the effect of ATPgS7antagonists on
cytokine and chemokine measurements (Figure 2), analysis of
variance with repeated measures was used to test for mean level
differences among the groups. Dunnett–Hsu adjustments were used
to test for differences among groups versus a control group.
Conditioned supernatants of cells receiving antagonists and ATPgS
were compared to ATPgS 10 or 100 mM alone as indicated.
Conditioned supernatants of cells receiving ATPgS alone or
antagonists alone were compared to cells cultured in the absence
of purinergic agents. For ICAM-1 expression, cells receiving
antagonist and ATPgS were compared to cells receiving ATPgS
alone. ICAM-1 expression of cells receiving ATPgS alone or
antagonist alone was compared to basal ICAM-1 expression. These
analyses were performed using the SAS statistical package, version
9.1 (SAS Institute, Inc., Cary, NC). Mean values were considered to
be significantly different when Pp0.05.
All experiments performed had institutional approval.
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